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Pulmonary artery pressure in association with serum
parathormone in maintenance hemodialysis patients
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A b s t r a c t
Introduction: There are several potential explanations for the development of PH
in patients with stable hemodialysis patients. Hormonal and metabolic
derangement associated with end-stage renal failure might lead to pulmonary
arterial vasoconstriction and an increase of the pulmonary vascular resistance.
The aim of this study was to consider the association of pulmonary artery
pressure (PAP) with serum parathormone in end-stage renal disease (ESRD)
patients under regular hemodialysis treatment. 
Material and methods: This cross-sectional study was conducted on patients
with end-stage renal disease undergoing maintenance hemodialysis treatment
through an arteriovenous fistula which was created on the hand, and with acetate
basis dialysate and polysulfone membranes. For all patients serum intact
parathormone (iPTH) was measured. For assessment of pulmonary artery
pressure, all patients were subjected to two-dimensional and doppler
echocardiographic studies that were done for the patients after their hemodialysis
sessions. 
Results: The study comprised 102 patients  (F=46, M=56) consisting of 73 non
diabetic hemodialysis patients (F=33, M=40), and 29 diabetic hemodialysis
patients (F=13, M=16). The duration of hemodialysis was 17.8±29 months. The
mean ±SD of serum iPTH of total patients was 338±306 pg/ml. The mean ±SD of
pulmonary artery systolic pressure (PAP) was 41.5±12.6 mmHg. A significant
positive correlation of PAP with the dosage (r=0.36, p=0.001) and duration of
hemodialysis (r=0.35, p<0.001) was seen, also a significant positive correlation
of pulmonary artery systolic pressure with serum intact parathormone (iPTH) in
hemodialysis patients was found. 
Conclusions: A significant positive correlation of serum intact parathormone with
pulmonary artery pressure, which is a new aspect of uncontrolled secondary
hyperparathyroidism implies the need for a better control of poorly controlled
hyperparathyroidism disease in hemodialysis patients.
Key words: pulmonary hypertension, pulmonary artery pressure (PAP), hemodialysis,
end-stage renal failure, parathormone.
Introduction
Cardiovascular disease (CVD) remains the main cause of morbidity and
mortality in patients with end-stage renal disease (ESRD) [1, 2]. Left ventricular
hypertrophy (LVH), interstitial myocardial fibrosis, arteriolar wall thickening
and coronary artery calcification are hallmarks of this disorder [3, 4]. Although
traditional risk factors such as diabetes mellitus, hypertension, dyslipidemia
and advanced age, are prevalent in ESRD patients, they may not be sufficient
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by themselves to account for the high prevalence of
CVD in patients with this condition [1]. Thus the search
for other non-traditional risk factors that may be
involved in the pathogenesis of uremic CVD has been
an area of intense study [1, 5]. There is growing
evidence to suggest that abnormalities in serum
parathyroid hormone (PTH) levels are resulting in
vascular and visceral calcification leading to an
increased risk of cardiovascular morbidity and mortality
in these patients [6, 7]. Secondary hyperparathyroidism
is often found to be an independent risk factor for
uremic calcification. Serum PTH contributes to
cardiovascular complications in many ways [6, 8]. It
has a permissive role in arteriolar wall thickening,
myocardial interstitial fibrosis [9] promoting
hyperlipidemia and hypertension [10-12]. It was
suggested that the abnormalities in right ventricular
function in patients with end-stage renal disease
(ESRD) are in largely due to pulmonary hypertension
(PH) which may develop secondary to ESRD [13, 14].
There are several potential explanations for the
development of PH in patients with ESRD, hormonal
and metabolic derangement associated with ESRD
might lead to pulmonary arterial vasoconstriction and
an increase of the pulmonary vascular resistance [13,
7]. The parathyroid hormone is known to enhance the
entry of calcium into many cells, chronic exposure to
excess blood levels of PTH is associated with increased
calcium content of many tissues [4, 7, 13].
Cardiovascular cells (cardiomyocytes and smooth
muscle cells) are target cells for the parathyroid
hormone [7, 15]. In addition to the cardiovascular
effects of secondary hyperparathyroidism (SHPTH), it
has been shown that high serum parathormone is
associated with an increased incidence of hypertension
[7, 16]. Therefore, it is possible that SHPTH in
hemodialysis patients may also have some effects to
increase the pulmonary artery pressure. Studies
concerning the effect of high serum PTH on the
pulmonary artery systolic pressure (PAP) increment
are scarce and controversial, we therefore aimed to
consider the association of serum parathormone with
PAP in ESRD patients who are undergoing regular
hemodialysis treatment.
Material and methods
This is a cross-sectional study conducted on
patients with end-stage renal disease undergoing
maintenance hemodialysis treatment through an
arteriovenous fistula which was created on the hand,
and with acetate basis dialysate and polysulfone
membranes. The study was carried-out in the
hemodialysis section of Hajar Medical Educational &
Therapeutic Center of Shahrekord University of
Medical Sciences in Shahrekord of Iran. Blood samples
were collected after an overnight fast. In all patients
serum intact parathormone (iPTH) was determined
by the radio-immuno assay (RIA) method using DSL-
8000 kits of the USA (normal range of values is 10-65
pg/ml). The patients were under hemodialysis (HD)
for two or three times per week. Exclusion criteria
were past history of chronic obstructive lung disease
(COPD), multiple lung infections, cigarette smoking,
history of cough, allergy, asthma, using drugs affects
pulmonary function or structure, chest wall or
parenchymal lung disease, previous pulmonary
embolism, systemic lupus erythmatosous, left-to-right
shunt, and significant mitral or aortic valve disease
and also any other past history of lung disease and
also any lung abnormality on the chest x-ray.
According to the severity of secondary
hyperparathyroidism, each patient being treated for
secondary hyperparathyroidism (SHPTH) was given
oral active vitamin D3 (Rocaltrol), calcium carbonate
capsule, and Rena-Gel tablets at various doses. After
their hemodialysis session, the patients were
subjected to two-dimensional and doppler
echocardiographic studies. Systolic right ventricular
(or pulmonary artery) pressure was calculated using
the Bernoulli equation (p=4 v2, where p is the pressure
drop [mmHg] and v is the velocity of blood flow
[m/sec]), the pressure in the RV can be calculated by
RV pressure = RA pressure + (4 x [TR jet velocity]2) [17,
18]. All echocardiographic studies were done by a
single cardiologist. Pulmonary hypertension (PH) was
defined as a systolic PAP greater than or equal to 35
mmHg [14, 17, 18]. Duration and doses of hemodialysis
treatment were calculated from patient’s records and
the duration of each hemodialysis session was four
hours. For 3 years before the study, the polysulfone
membranes had been used in our hemodialysis center.
For the statistical analysis descriptive data are
expressed as mean ±SD. A comparison between
groups was considered using the students’ t test. For
correlations the partial correlation test was used. All
statistical analysis was performed using the SPSS
(version 11.5.00). The statistical analysis was
considered significant when p<0.05.
Results
The total patients were 102 (F=46, M=56) under
hemodialysis due to end-stage renal disease (ESRD)
consisting of 73 non diabetic hemodialysis patients
(F=33, M=40), and 29 diabetic hemodialysis patients
(F=13, M=16). Table I shows the mean ±SD of age,
the length of the time patients had been on
hemodialysis, dialysis dosage and serum values of
iPTH. The mean ±SD of age of total patients were
51±17.6 years. The length of the time patients had
been on hemodialysis were 17.8±29 months. Mean
±SD of serum iPTH of total patients were 338±306
pg/ml. Mean ±SD of iPTH of diabetic group and
nondiabetic group were 272±237 pg/ml and 364±327
pg/ml respectively. Mean ±SD of pulmonary artery
systolic pressure (PAP) of total HD patients, diabetic
HD group and non diabetic hemodialysis were
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41.5±12.6, 45±9.8 and 40±18 mmHg respectively. In
this study no significant difference of serum iPTH
between diabetics and nondiabetic hemodialysis
patients was found (p NS). A significant positive
correlation of PAP with dosage (r=0.36, p=0.001) and
duration of hemodialysis (r=0.35, p<0.001) (data
adjusted for ages of patients for two above
correlations) were seen. A significant positive
correlation of pulmonary artery systolic pressure with
serum intact parathormone (iPTH) in hemodialysis
patients was found (r=0.20, p=0.040; Figure 1) (data
adjusted for ages of patients).
Discussion
In this study, significant positive correlations of PAP
with hemodialysis duration and dosage were seen, also
a significant positive correlation of pulmonary artery
systolic pressure with serum intact parathormone was
found, too. Studies regarding the prevalence and the
predictors of pulmonary hypertension (PH) in patients
with end-stage renal failure undergoing regular
hemodialysis are quite scarce. Yigla et al. in a study on
58 patients with ESRD  receiving long-term hemodia-
lysis and on control groups of 5 patients receiving
peritoneal dialysis (PD) and 12 predialysis patients,
found a 39.7% of pulmonary hypertension in patients
who where under hemodialysis, (mean ±SD =44±7
mmHg; range, 37 to 65 mmHg) [14]. Amin et al. in a
study on 51 patients (28 men and 23 women) with
end-stage renal disease, who were receiving regular
hemodialysis PH was detected in 15 patients (29%),
this study showed women had a higher prevalence of
PH (48% vs 14%), moreover in this study there were
no significant differences between patients with PH
and those without PH with regard to age, duration of
dialysis, serum calcium, phosphorus, alkaline
phosphatase, parathyroid hormone (PTH) or the
prevalence of an abnormal (99m)Tc diphosphate lung
scan result (60% vs 73%, respectively). They showed
that 29% of patients with ESRD receiving regular
hemodialysis have PH and the presence of PH was not
related to the level of PTH or the severity of other
metabolic abnormalities, also there was no relation
Table I. Mean ±SD, minimum and maximum of age, duration, dose and also laboratory results of all patients and non-diabetic
and diabetic groups
Total HD patients Minimum Maximum Mean ±SD
N=102
Age [years] 14 84 51±17.6
DH* [months] 1 145 17.8±29
Dialysis
dose sessions 12 1740 199±349
iPTH [pg/ml] 5 1980 338±306
PASP [mmHg] 20 80 41.5±12.6
Non diabetics
N=73
Age [years] 14 84 48.3±18
DH* [months] 1 145 18.8±31
Dialysis
dose sessions 12 1740 208±375 
iPTH [pg/ml] 10 1980 364±327
PASP [mmHg] 20 80 40±18
Diabetics
N=29
Age [years] 15 79 58±15
DH* [months] 2 110 15±22
Dialysis
dose sessions 15 1300 175±277
iPTH [pg/ml] 5 1000 272±237
PASP [mmHg] 30 65 45±9.8
*duration of the hemodialysis treatment
Figure 1. A significant positive correlation of
pulmonary artery pressure with serum parathormone
in hemodialysis patients
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between PH and the presence or the severity of
pulmonary artery calcification. They also found that
PH is detected more frequently in women. Their study
does not support a role for secondary hyperparathy-
roidism as one of the etiologies of PH in patients with
ESRD [19]. Yigla also in an another study evaluated the
role of pulmonary calcification in the pathogenesis of
PH in patients with ESRD who receiving chronic HD
therapy by an A-V access. To consider the correlation
between pulmonary calcification expressed by lung
uptake of 99mTc-MDP and PH, selected 36 men and
13 women with a mean age of 61.7±13.2 years receiving
HD therapy for 38.2±43 months. Yigla concluded that
pulmonary calcification has no role in the pathogenesis
of PH among ESRD patients undergoing hemodialysis
therapy [20]. Our study is in agreement with previous
two studies in which ESRD patients under regular
hemodialysis had pulmonary hypertension. In contrast
to the Amin’s study, only our female diabetic
hemodialysis patients had PAP more than male
diabetic patients. In contrast to the above mentioned
studies we could show a significant positive correlation
of serum iPTH with pulmonary artery pressure. The
influence of high serum parathormone hormone
concentration on pulmonary pressure may be through
an increasing calcium content of the smooth muscle
cells of the artery [4, 7, 13]. Previously we shown that
high serum parathormone is associated with an
increased incidence of systemic hypertension in stable
hemodialysis patients [7]. Indeed, the parathyroid
hormone is known to enhance the entry of calcium
into many cells, chronic exposure to excess blood levels
of PTH is associated with increased calcium content
of many tissues [4, 7, 13]. 
Conclusions
In conclusion, a positive association of high serum
parathormone and pulmonary artery pressure is very
important because pulmonary hypertension is a
disease with poor prognosis and implies the need for
a better control of secondary hyperparathyroidism in
hemodialysis patientsm through controlling of
hyperphosphatemia.
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